BTK and diffuse large B-cell lymphoma: Other findings were as follows: ABC-DLBCL patients in the MCD cluster responded pretty well to ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor (BTKi); the genetic fingerprint of the N1 cluster appeared in the ABC subtype 95% of the time; and EZH2 mutations and BCL2 translocations frequently happened in tandem in GCB [56].